M&A Deal Summary

ArchiMed Acquires Natus

On July 21, 2022, private equity firm ArchiMed acquired medical products company Natus for 1.1B USD

Acquisition Highlights
  • This is ArchiMed’s 9th transaction in the Medical Products sector.
  • This is ArchiMed’s largest (disclosed) transaction.
  • This is ArchiMed’s 7th transaction in the United States.
  • This is ArchiMed’s 2nd transaction in Wisconsin.

M&A Deal Summary
Date 2022-07-21
Target Natus
Sector Medical Products
Buyer(s) ArchiMed
Deal Type Going Private
Deal Value 1.1B USD
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
Davis Polk & Wardwell (Legal)

Target

Natus

Middleton, Wisconsin, United States
Natus is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Natus was founded in 1987 and is based in Pleasanton, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ArchiMed

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 31 of 36
Sector (Medical Products) 9 of 9
Type (Going Private) 2 of 3
State (Wisconsin) 2 of 2
Country (United States) 7 of 9
Year (2022) 3 of 4
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-12 Title21

Phoenix, Arizona, United States

Title21 is a provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders like spinal muscular atrophy, and diseases caused by vital infection, including COVID-19. Title21 was formed in 2001 and is based in Pleasanton, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-08 Bomi Group

Spino d’Adda, Italy

Bomi Group runs cutting-edge transport, warehousing, and supply chain management services for healthcare companies ranging from pharmaceutical and medical equipment manufacturers to hospitals, testing laboratories, and outpatient service providers. Bomi Group was formed in `1985 and is based in Spino d’Adda, Italy.

Sell -
Mergr

Product

Company

Legal